JP2012503664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503664A5 JP2012503664A5 JP2011529154A JP2011529154A JP2012503664A5 JP 2012503664 A5 JP2012503664 A5 JP 2012503664A5 JP 2011529154 A JP2011529154 A JP 2011529154A JP 2011529154 A JP2011529154 A JP 2011529154A JP 2012503664 A5 JP2012503664 A5 JP 2012503664A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- methylsulfanyl
- pyridine
- oxazol
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 2 - methylsulfanyl-oxazol-5-yl Chemical group 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- IYMYCOCMDBLWOY-JEDNCBNOSA-N (1s)-1-(2-methylsulfanyl-1,3-oxazol-5-yl)propan-1-amine;hydrochloride Chemical compound Cl.CC[C@H](N)C1=CN=C(SC)O1 IYMYCOCMDBLWOY-JEDNCBNOSA-N 0.000 description 3
- SVXOOOYHPUKMQG-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[[4-(4-methylpiperazin-1-yl)sulfonylphenyl]methyl]pyrazolo[3,4-c]pyridine-4-carboxamide Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1CNC(=O)C1=CN=CC2=C1C=NN2C1=CC=C(F)C=C1 SVXOOOYHPUKMQG-UHFFFAOYSA-N 0.000 description 3
- UEZKWPBPQQSIMH-UHFFFAOYSA-N 2-[[5-[[[1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carbonyl]amino]methyl]pyridin-2-yl]sulfonyl-methylamino]ethyl acetate Chemical compound C1=NC(S(=O)(=O)N(CCOC(C)=O)C)=CC=C1CNC(=O)C1=CN=CC2=C1C=NN2C1=CC=C(F)C=C1 UEZKWPBPQQSIMH-UHFFFAOYSA-N 0.000 description 3
- YKZYEUAXINVCEK-UHFFFAOYSA-N 2-methylsulfanyl-1,3-oxazole-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)O1 YKZYEUAXINVCEK-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- AQBJFVCKUVWMLP-UHFFFAOYSA-N ethyl 2-ethylsulfanyl-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SCC)O1 AQBJFVCKUVWMLP-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- PYNUOAIJIQGACY-UHFFFAOYSA-N propylazanium;chloride Chemical compound Cl.CCCN PYNUOAIJIQGACY-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VVUSTAJOHMIPTA-NSHDSACASA-N 1-(4-fluorophenyl)-n-[(1s)-1-(2-methylsulfanyl-1,3-oxazol-5-yl)ethyl]pyrazolo[3,4-c]pyridine-4-carboxamide Chemical compound O1C(SC)=NC=C1[C@H](C)NC(=O)C1=CN=CC2=C1C=NN2C1=CC=C(F)C=C1 VVUSTAJOHMIPTA-NSHDSACASA-N 0.000 description 1
- QKDVCGNAAZDXBZ-INIZCTEOSA-N 1-(4-fluorophenyl)-n-[(1s)-1-(2-methylsulfanyl-1,3-oxazol-5-yl)propyl]pyrazolo[3,4-c]pyridine-4-carboxamide Chemical compound N([C@@H](CC)C=1OC(SC)=NC=1)C(=O)C(C=1C=N2)=CN=CC=1N2C1=CC=C(F)C=C1 QKDVCGNAAZDXBZ-INIZCTEOSA-N 0.000 description 1
- JTXOGWNTNOJMLN-UHFFFAOYSA-N 1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carboxylic acid Chemical compound N1=CC=2C(C(=O)O)=CN=CC=2N1C1=CC=C(F)C=C1 JTXOGWNTNOJMLN-UHFFFAOYSA-N 0.000 description 1
- BTIDLVRPONKKEW-UHFFFAOYSA-N 2-methylsulfanyl-1,3-oxazole-4-carboxylic acid Chemical compound CSC1=NC(C(O)=O)=CO1 BTIDLVRPONKKEW-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- ZFLDTEIDAGWEEI-UHFFFAOYSA-N ethyl 2-chloro-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)O1 ZFLDTEIDAGWEEI-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical group [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10040108P | 2008-09-26 | 2008-09-26 | |
| US61/100,401 | 2008-09-26 | ||
| PCT/US2009/057778 WO2010036632A1 (en) | 2008-09-26 | 2009-09-22 | Azaindazole compounds as ccr1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503664A JP2012503664A (ja) | 2012-02-09 |
| JP2012503664A5 true JP2012503664A5 (enExample) | 2012-05-24 |
| JP5507567B2 JP5507567B2 (ja) | 2014-05-28 |
Family
ID=41349302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529154A Active JP5507567B2 (ja) | 2008-09-26 | 2009-09-22 | Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US7879873B2 (enExample) |
| EP (1) | EP2346868B1 (enExample) |
| JP (1) | JP5507567B2 (enExample) |
| KR (1) | KR20110060904A (enExample) |
| CN (1) | CN102227425A (enExample) |
| AP (1) | AP2739A (enExample) |
| AR (1) | AR073689A1 (enExample) |
| AU (1) | AU2009296839A1 (enExample) |
| BR (1) | BRPI0919844A2 (enExample) |
| CA (1) | CA2737472A1 (enExample) |
| CL (1) | CL2011000668A1 (enExample) |
| CO (1) | CO6351735A2 (enExample) |
| EA (1) | EA201100524A1 (enExample) |
| EC (1) | ECSP11010932A (enExample) |
| IL (1) | IL210857A0 (enExample) |
| MA (1) | MA32655B1 (enExample) |
| MX (1) | MX2011002951A (enExample) |
| NZ (1) | NZ591115A (enExample) |
| PE (1) | PE20110854A1 (enExample) |
| TW (1) | TW201018683A (enExample) |
| UA (1) | UA103634C2 (enExample) |
| UY (1) | UY32140A (enExample) |
| WO (1) | WO2010036632A1 (enExample) |
| ZA (1) | ZA201100625B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008327B2 (en) | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| CA2737472A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
| KR101700229B1 (ko) * | 2009-03-19 | 2017-01-26 | 메디칼 리서치 카운실 테크놀로지 | 화합물들 |
| WO2011049917A1 (en) | 2009-10-21 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| AU2010328480A1 (en) * | 2009-12-08 | 2012-05-17 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| EP2388260A1 (de) * | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
| SG188367A1 (en) | 2010-09-03 | 2013-04-30 | Forma Tm Llc | Novel compounds and compositions for the inhibition of nampt |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CN102775365A (zh) * | 2011-05-10 | 2012-11-14 | 无锡立诺康医药科技有限公司 | 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺 |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| US9174984B2 (en) | 2011-10-24 | 2015-11-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds |
| US20140329809A1 (en) | 2011-10-28 | 2014-11-06 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| JP2015508785A (ja) * | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| AR091858A1 (es) * | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| WO2014144747A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| FR3016879A1 (fr) * | 2014-01-29 | 2015-07-31 | Guillaume Laconde | Procede de preparation de benzotriazole n-acyles |
| TR201809388T4 (tr) | 2014-03-17 | 2018-07-23 | Pfizer | Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri. |
| WO2015160654A1 (en) | 2014-04-14 | 2015-10-22 | Boehringer Ingelheim International Gmbh | Compounds as modulators of ror gamma |
| CO2018004165A2 (es) | 2015-10-23 | 2018-09-20 | Vifor Int Ag | Inhibidores de ferroportina |
| EP3373733A1 (en) | 2015-11-13 | 2018-09-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| US20180354920A1 (en) | 2015-11-13 | 2018-12-13 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3426255B1 (en) | 2016-03-07 | 2022-11-30 | The Global Alliance for TB Drug Development, Inc. | Antibacterial compounds and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| CN111393376B (zh) * | 2020-05-11 | 2022-05-13 | 安徽赛迪生物科技有限公司 | 一种2-氯嘧啶-4-甲酸的合成方法 |
| WO2021262878A1 (en) * | 2020-06-24 | 2021-12-30 | Oregon Health & Science University | Novel molecule for modulation of innate immune responses controlled by sting protein |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| US4999363A (en) | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| CZ289756B6 (cs) | 1991-03-28 | 2002-04-17 | Eisai Co., Ltd. | Heterocyklicko-cyklické aminové deriváty, meziprodukty postupu přípravy těchto sloučenin, farmaceutický prostředek a pouľití uvedených derivátů |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5616537A (en) | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
| ES2122290T3 (es) | 1993-06-25 | 1998-12-16 | Kumiai Chemical Industry Co | Derivado de indazolsulfonilurea, su utilizacion e intermediario para su produccion. |
| AU699281B2 (en) | 1994-12-06 | 1998-11-26 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| WO1997023480A1 (en) | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| EP1040100A1 (en) | 1997-11-04 | 2000-10-04 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7058826B2 (en) * | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| WO2003037274A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| AU2002357312A1 (en) * | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
| JP4578106B2 (ja) | 2002-04-11 | 2010-11-10 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカインインヒビターとしてのヘテロ環式アミド誘導体 |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| JP2007502307A (ja) | 2003-08-15 | 2007-02-08 | アストラゼネカ アクチボラグ | グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環 |
| WO2006091496A2 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| GB0504828D0 (en) * | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006125119A1 (en) | 2005-05-17 | 2006-11-23 | Sarcode Corporation | Compositions and methods for treatment of eye disorders |
| HRP20150832T1 (hr) * | 2005-06-22 | 2015-09-25 | Chemocentryx, Inc. | Spojevi azaindazola i postupci njihove upotrebe |
| ES2397400T3 (es) | 2005-09-01 | 2013-03-06 | Eli Lilly & Company | 6-arilalquilamino-2,3,4,5-tetrahidro-1H-benzo[D]azepinas como agonistas del receptor 5-HT2C |
| JP2009513677A (ja) | 2005-10-25 | 2009-04-02 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| EP2044055A4 (en) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
| TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| NZ582349A (en) * | 2007-06-29 | 2012-06-29 | Sunesis Pharmaceuticals Inc | Heterocyclic compounds useful as raf kinase inhibitors |
| CN101815718A (zh) | 2007-08-10 | 2010-08-25 | 克里斯捷诺米有限公司 | 吡啶衍生物及其用法 |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009085256A1 (en) * | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| US8008327B2 (en) | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| CA2737472A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
| WO2011049917A1 (en) | 2009-10-21 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| AU2010328480A1 (en) * | 2009-12-08 | 2012-05-17 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2009
- 2009-09-22 CA CA2737472A patent/CA2737472A1/en not_active Abandoned
- 2009-09-22 EP EP09792818.8A patent/EP2346868B1/en active Active
- 2009-09-22 NZ NZ591115A patent/NZ591115A/xx not_active IP Right Cessation
- 2009-09-22 AU AU2009296839A patent/AU2009296839A1/en not_active Abandoned
- 2009-09-22 BR BRPI0919844A patent/BRPI0919844A2/pt not_active IP Right Cessation
- 2009-09-22 KR KR1020117006720A patent/KR20110060904A/ko not_active Withdrawn
- 2009-09-22 CN CN2009801472064A patent/CN102227425A/zh active Pending
- 2009-09-22 WO PCT/US2009/057778 patent/WO2010036632A1/en not_active Ceased
- 2009-09-22 JP JP2011529154A patent/JP5507567B2/ja active Active
- 2009-09-22 US US12/564,129 patent/US7879873B2/en active Active
- 2009-09-22 EA EA201100524A patent/EA201100524A1/ru unknown
- 2009-09-22 PE PE2011000789A patent/PE20110854A1/es not_active Application Discontinuation
- 2009-09-22 UA UAA201105061A patent/UA103634C2/ru unknown
- 2009-09-22 MX MX2011002951A patent/MX2011002951A/es active IP Right Grant
- 2009-09-22 AP AP2011005685A patent/AP2739A/xx active
- 2009-09-24 UY UY0001032140A patent/UY32140A/es not_active Application Discontinuation
- 2009-09-25 TW TW098132530A patent/TW201018683A/zh unknown
- 2009-09-25 AR ARP090103709A patent/AR073689A1/es unknown
-
2010
- 2010-12-16 US US12/969,753 patent/US8063065B2/en active Active
-
2011
- 2011-01-25 ZA ZA2011/00625A patent/ZA201100625B/en unknown
- 2011-01-25 IL IL210857A patent/IL210857A0/en unknown
- 2011-03-17 CO CO11033549A patent/CO6351735A2/es active IP Right Grant
- 2011-03-24 MA MA33724A patent/MA32655B1/fr unknown
- 2011-03-25 CL CL2011000668A patent/CL2011000668A1/es unknown
- 2011-03-29 EC EC2011010932A patent/ECSP11010932A/es unknown
- 2011-10-14 US US13/273,509 patent/US8163918B2/en active Active
-
2012
- 2012-02-08 US US13/368,397 patent/US8338610B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503664A5 (enExample) | ||
| CN101993405B (zh) | 吲哚啉衍生物、及其制备方法和用途 | |
| CN103842359B (zh) | N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 | |
| CN1056372C (zh) | 噻唑烷二酮衍生物,它们的制备方法和用途 | |
| JP2012521377A5 (enExample) | ||
| CZ172397A3 (en) | Novel benzimidazole derivatives with antihistaminic activity | |
| NZ520028A (en) | Benzimidazole derivatives | |
| JPH02134377A (ja) | ビペリジニルベンズイミダゾール類 | |
| IE64205B1 (en) | Muscarinic receptor antagonists | |
| JP2009531465A5 (enExample) | ||
| CN106831737B (zh) | 维帕他韦及其衍生物的制备 | |
| JP3626191B2 (ja) | 心臓血管系に活性な２−アミノ−１，２，３，４−テトラヒドロナフタレン誘導体 | |
| JP2013515755A5 (enExample) | ||
| NL7907040A (nl) | Nieuwe derivaten van 3-(aminoethyl) fenol en zouten daarvan, werkwijze ter bereiding daarvan, de toepas- sing daarvan als geneesmiddelen en farmaceutische preparaten, die deze nieuwe derivaten bevatten. | |
| JP2009541290A5 (enExample) | ||
| CN100406009C (zh) | 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物 | |
| BRPI0717100A2 (pt) | Derivados de pirrolizina, indolizina e quinolizina, o respectivo preparo e a respectiva aplicação em terapêutica | |
| CN101484445A (zh) | 吡咯烷取代的黄酮的对映选择性合成 | |
| WO2009086728A1 (zh) | 一种制备瑞格列奈的方法 | |
| JP2002538117A (ja) | 肥満の予防または治療のための医薬の製造のための多環２−アミノチアゾール系の使用 | |
| US20100137613A1 (en) | Process for eprosartan | |
| JP2002538148A (ja) | 多環２−アミノチアゾール系、その製造方法およびそれを含む医薬 | |
| EP1309577A2 (en) | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | |
| CN101311179A (zh) | 制备噻吩并-苯并二氮杂卓类化合物的改进方法 | |
| JPWO1997005091A1 (ja) | ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 |